In this podcast episode, Prithviraj Bose, MD, and Andrew Kuykendall, MD, discuss their contemporary approaches to the treatment of patients with essential thrombocythemia. 

The topics covered include:

• When to use cytoreduction therapies and which therapies to use in low-risk patients
• Type 1 and type 2 CALR mutations and addressing patient concerns with data from sequencing reports
• Experts’ thoughts on therapy options in higher-risk patients

Presenters:

Prithviraj Bose, MD

Associate Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Andrew Kuykendall, MD
Assistant Professor 
Department of Oncologic Sciences
University of South Florida
Assistant Member
Malignant Hematology
H. Lee Moffitt Cancer Center
Tampa, Florida
 

Content for this program was supported by educational grants from GSK, Incyte Corporation, and PharmaEssentia Corp.

Link to the full program, including downloadable slides and an on-demand webcast from the live event:
bit.ly/3XF3cSF